Most Recent
In a win for ASIC, a judge has found that former oil and gas company Antares Energy violated its continuous disclosure obligations by failing to reveal the name of the buyer behind an ill-fated US$254 million acquisition of Texan oil assets.
The Australian Taxation Office has secured a Full Federal Court victory in its $60 million tax battle with Healius, overturning a ruling that found the healthcare company could claw back a multi-million dollar tax refund.
The Federal Court has upheld Novartis' appeal of a ruling revoking its patent for an oral form of multiple sclerosis drug Gilenya, after Australian generic drug maker Arrow Pharmaceuticals dropped its opposition to the patent despite prevailing before IP Australia.
Mosaic Brands has taken the Australian Communications and Media Authority to court, alleging a request for documents based on suspected Spam Act violations is invalid.
Changes to AMP's buyer of last resort policy that reduced the multiple by which the wealth management firm would purchase advisers' client registers was necessary to protect the business from a 'BOLR run', a court had been told.
US women's clothing retailer Ann Taylor has come up short in its opposition to Nike's bid to register the 'Aeoroloft' mark for its brand of lightweight fitness apparel, with an IP Australia finding the mark is not deceptively similar to Ann Taylor's 'Loft' mark.
Fintech Zip Co has successfully opposed rival Flexigroup's attempt to trade mark 'No Interest Ever!', in the latest trade mark battle between buy now, pay later service providers in Australia.
Australia's leading livestock group cannot block US company Branhaven from amending its application for a bovine genome patent, which the group has worried could harm the Australian cattle industry's ability to use genetic tests.
A former associate director of a Melbourne law firm that allegedly sacked him after he complained of workplace "sniping" has resolved his unfair dismissal lawsuit.
Merck Sharp & Dohme has dropped a lawsuit brought against a unit of Indian generic manufacturer Lupin for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Januvia and Janumet.